DOCSLIB.ORG

Procedure Description Charge Amount 1302300005 ROOM MED

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Charge Procedure Description Amount 1302300005 ROOM MED SURG W TELEMETRY ENU 1,360.00 1302300012 ROOM MED SURG ENU 850.00 1302300019 ROOM SWING CUSTODIAL ENU 220.00 1302300020 ROOM SWING SKILL ENU 235.00 1302300043 ROOM HOSPICE BED ENU 765.00 1302300052 ROOM RESPITE CARE BED ENU 765.00 1302302346 OUTSIDE SERVICE FEE VAR SUP 1302310079 CATH INDWELL BLADDER SIMPLE 210.00 1302310109 CODE BLUE 1,035.00 1302310304 OBSERVATION PER HR 40.00 1302310305 OBSERVATION PER HR TELEMETRY 64.00 1302310556 NONBILLABLE OBSERVATION HR 0.00 1302310557 OBSERVATION DIRECT ADM 130.00 1302320288 SYSTEM CHEST TUBE 312.00 1302320935 SUPPLIES PICC LINE 230.00 1302322214 WOUND VAC FOAM 110.00 1302322259 BOOT WAFFLE 108.00 1302322407 KIT PREVALON TURNING POSITION 550.00 1302322466 HANGER BRACE SERVICE VAR SUP 1302350451 IV INF THERAPEUTIC EA ADD HR 210.00 1302350453 IV INF THERAPEUTIC UP TO 1HR 635.00 1302350457 GASTRIC INTUBATION/LAVAGE 930.00 1302350480 INSERT VENOUS CENTRAL LINE 1,660.00 1302350484 INJECTION SUB-Q/IM 125.00 1302350490 IV PUSH INITIAL DRUG 234.00 1302350603 IV PUSH EA SEQUENTIAL DRUG 153.00 1302350885 ADMIN IMMUNIZATION 120.00 1302350895 EXCISION NAIL & MATRIX 880.00 1302360067 ADMIN PNEUMOCOCCAL VACCINE 94.00 1302360068 ADMIN INFLUENZA VIRUS VACINE 94.00 1302360263 ADMIN TB SKIN TEST 77.00 1302360269 US PV RESIDUAL URINE 230.00 1302360274 IV PUSH EA ADD DRUG 168.00 1302360275 IV INF CONCURRENT THERAPEUTIC 345.00 1302360276 IV INF SEQUENTIAL THER UP TO 1 210.00 1302360293 INSERT STRAIGHT CATH THERAPEUT 195.00 1302360373 IV INF HYDRATION EA ADD HR 170.00 1302360374 IV INF HYDRATION UP TO 1HR 585.00 1302360696 BLOOD TRANSFUSION DAILY 1,020.00 1302360801 CATH FOR URINE SPECIMEN 21.00 1302360804 NURSING E/M ESTAB LVL 1 100.00 1314010056 BIPAP SETUP/SUPPLIES 204.00 1314010541 PULMONARY STRESS TEST 400.00 1314020026 AMBUBAG 42.00 1314020103 STRAP BIPAP CHIN 29.00 1314020104 CIRCUIT BIPAP 39.00 1314020105 STRAP BIPAP HEAD 27.00 1314020106 MASK BIPAP 60.00 1314020293 CIRCUIT IPPB 10.00 1314020629 SETUP/SUPPLIES HHN 24.00 1314020679 KIT ASTHMA 121.00 1314020747 SPACER MDI 48.00 1314020866 OXYGEN DAILY CHARGE 194.00 1314020920 DEVICE PEAK FLOW 47.00 1314021291 FLUTTER VALVE SUPPLY 92.00 1314022288 HHF WWO OXYGEN DAILY 194.00 1314050232 SPIROMETERY PULMONARY FUNCTION 190.00 1314050320 PULSE OXIMETRY PRE/POST EXER 74.00 1314050321 PULSE OXIMETRY OVERNIGHT 470.00 1314050323 PULSE OXIMETRY ASSESSMENT 48.00 1314050325 PULSE OXIMETER DAILY CHARGE 470.00 1314050354 CHEST PT MANUAL EA ADD 103.00 1314050355 CHEST PT MANUAL INITIAL 103.00 1314050359 PH ANALYSIS PLEURAL FLUID 80.00 1314050360 PH ANALYSIS ARTERIAL BLOOD 100.00 1314050361 PFT PROVOCHOLINE CHALLENGE 855.00 1314050362 PFT PRE-POST BRONCHODILATOR 550.00 1314050383 PEAK FLOW MEASUREMENT 60.00 1314050401 NEBULIZER TX PENTAMIDINE 385.00 1314050456 IONIZED CALCIUM 130.00 1314050522 INCENTIVE SPIROMETER W INSTRUC 130.00 1314050561 GLUCOSE 75.00 1314050605 ELECTROLYTE PANEL 115.00 1314050633 EEG AWAKE/ASLEEP/PHOTIC/HV 1,430.00 1314050677 COOXIMETRY 93.00 1314050802 BIPAP DAILY CHARGE 365.00 1314050816 ARTERIAL PUNCTURE W BLOOD DRW 44.00 1314050878 BLOOD GAS ANALYSIS 235.00 1314050889 ACT-ACTIVATED CLOTTING TIME 81.00 1314050893 REQUEST FOR SERVICE 0.00 1314060010 HOME RESP THERAPY DEMO 145.00 1314060021 EEG EXTENDED MONITOR > 1 HR 1,400.00 1314060022 EEG EXTENDED MONITOR 41-60M 1,255.00 1314060273 VENT CHARGE FIRST DAY 1,700.00 1314060296 BEDSIDE SPIRO PRE&POST BRONCHO 550.00 1314060297 BEDSIDE SPIROMETRY 190.00 1314060853 PLETHYS LUNG VOL/AIRWAY RESIST 710.00 1314060854 DIFFUSING CAPACITY 260.00 1314061146 SLEEP STUDY W CPAP SERVICE 4,670.00 1314061147 SLEEP STUDY WO CPAP SERVICE 4,670.00 1314061167 SLEEP STUDY HOME UNATTENDED 475.00 1314061272 CHEST PT VEST INITIAL OR SUB 103.00 1314061273 RESP TX INITIAL OR SUB 120.00 1314090155 INSERT ART LINE 1,585.00 1314202201 CARDIAC RHB PH2 EXERCISE/EA 215.00 1314210488 HOLTER SCANNING UP TO 24 HR 475.00 1314220891 6 MINUTE WALK TEST 145.00 1314250310 AMB CARDIAC TELE UP TO 30 DAYS 155.00 1314250326 PULMONARY REHAB PH 2/ SESSION 93.00 1314250328 PULM REHAB PH 3/EACH 5.00 1314250610 EKG STRESS 765.00 1314250622 ECHO 2D M MODE LIMITED 745.00 1314250627 ECHO STRESS 1,485.00 1314250628 ECHO PEDS CONG ANOM LIMITED 1,075.00 1314250629 ECHO PED CONG ANOM COMP 935.00 1314250630 ECHO DOPPLER PW CW LIMITED 175.00 1314250631 ECHO DOPPLER PW CW COMPLETE 385.00 1314250632 ECHO DOPPLER COLOR VEL MAPPING 355.00 1314250667 HOLTER SCANNING 48 HR 440.00 1314250668 HOLTER RECORD/HOOKUP 48 HR 360.00 1314250779 CARDIAC REHAB PH 3/ EACH 5.00 1314250923 ECHO 2D M MODE COMPLETE 1,485.00 1314250928 HOLTER RECD/HOOK UPTO 24H 480.00 1314250932 EKG 195.00 1314250989 ECHO CONTRAST 1.5 ML 312.00 1314260245 EKG PEDS 195.00 1314260388 STRESS ECHO C CON/ECHO PORTN 2,170.00 1314260673 CARD REHAB P2 NONMONITOR EXER 115.00 1314261189 ECHO 2D MMODE COMPLETE W CON 2,170.00 1314261190 ECHO 2D M MODE LIMITED W CON 1,150.00 1314261324 ECHO STRESS W EKG WO CONTRAST 2,250.00 1314261325 ECHO STRESS W EKG W CONTRAST 2,935.00 1314261326 ECHO STRESS WEKG WO CON WPHARM 2,250.00 1314261327 ECHO STRESS W EKG W CON WPHARM 2,935.00 1314261360 MYOCARDIAL STRAIN IMAGING 400.00 1321002341 CANNULA WO TROCAR 5 X 100 MM 14.00 1321002346 OUTSIDE SERVICE FEE VAR SUP 1321010000 INSERTION ARROW CATH 440.00 1321010003 3000CC LR NACL OR H20 IRRIGANT 22.00 1321010049 AVITINE 404.00 1321010065 BROVIAC INSERTION 680.00 1321010072 CATARACT SURGERY PKG 3,480.00 1321010073 CATH INSERT LEONARD/HICKMAN 815.00 1321010086 CLASS I 625.00 1321010089 CLASS II 2,180.00 1321010093 CLASS III 2,750.00 1321010096 CLASS IV 4,195.00 1321010099 CLASS V 5,905.00 1321010102 CLASS VI 7,345.00 1321010109 CODE BLUE OR 1,430.00 1321010210 GLYCINE 1.5% 3000 CC 47.00 1321010223 INDIGO LASEROPTIC SYSTEM 5,572.00 1321010263 LITHOTRIPSY PROBE 554.00 1321010276 MISC OPERATING RM I 24.00 1321010277 MISC OPERATING RM II 170.00 1321010278 MISC OPERATING RM III 340.00 1321010279 MISC OR VAR SUP 1321010289 MYRINGOTOMY W TUBE 630.00 1321010432 SOL. SOD CHLOR.IRRIG. 1000 CC 58.00 1321010433 SOL. WATER IRRIG 1000 CC 58.00 1321010464 TTS DILATATION 450.00 1321010477 VITRECTOMY 850.00 1321010485 XYLOCAINE JELLY 2% 53.00 1321020027 ANCHORS VESICA SUTURE 649.00 1321020032 ANCHOR CLIP ANGLED 82-8591 124.00 1321020046 SUPPLIES ARTHROSCOPY 1,334.00 1321020052 AUTOSUTURE TA-90 LONG 237.00 1321020053 AUTOSUTURE CEEA 25/28/31 1,248.00 1321020054 AUTOSUTURE ROTIC. 55-3.5/4.8/ 1,321.00 1321020056 AUTOSUTURE TA90 3.5/4.8 493.00 1321020070 BAG UA DRAINAGE 2000CC 38.00 1321020071 BAG UA DRAINAGE 4000 CC 42.00 1321020072 BAG UA LEG 13.00 1321020077 BALLOON DILATION CATHETER 533.00 1321020079 BALLOON INSERT DATASCOPE 34/40 2,537.00 1321020080 BALLOON UROMAX 847.00 1321020090 BLANKET BEAR HUGGER 121.00 1321020095 BAG BILE 35.00 1321020102 FORCEPS BIOPSY DISP 81.00 1321020107 CAUTERY BIPOLAR CORD 20.00 1321020115 BLADE SAW ALL 209.00 1321020135 BONE PLUGS ORTHO 310.00 1321020142 SUPPLIES BOWEL 321.00 1321020144 SUPPLIES BREAST BIOPSY 123.00 1321020179 CAST LONG LEG 123.00 1321020184 CAST SHORT ARM 40.00 1321020185 CAST SHORT LEG 68.00 1321020187 CAST SYNTHETIC LONG ARM 272.00 1321020188 CAST SYNTHETIC LONG LEG 588.00 1321020189 CAST SYNTHETIC SHORT ARM 172.00 1321020190 CAST SYNTHETIC SHORT LEG 295.00 1321020204 CATH FOLEY 24 30 CC 3 WAY 64.00 1321020205 CATH FOLEY ALL SIZES 59.00 1321020207 CATH GROSHONG MRI DUAL IMPLANT 2,233.00 1321020208 CATH GROSHONG MULTI LUMEN KIT0 1,193.00 1321020234 CATH SECURE 10.00 1321020236 CATH STAMEY 122.00 1321020246 CATH URETERAL 191.00 1321020249 CATHETER ALL PURPOSE 16FR 10.00 1321020266 CAUTERY EXTENDER 26.00 1321020268 CAUTERY SUCTION 35.00 1321020270 SUPPLIES CBI IRRIGATION 35.00 1321020273 CARTRIDGE CEMENT GUN 177.00 1321020289 CHOLANGIOCATH ALL SIZES 31.00 1321020290 SUPPLIES CHOLECYSTECTOMY 454.00 1321020296 CLASS VII 14,625.00 1321020305 CLIPS LARGE/ORANGE 77.00 1321020306 CLIPS MEDIUM/LARGE 40.00 1321020308 CLIPS SMALL/YELLOW 45.00 1321020344 CUFF TOURNIQUET 63.00 1321020354 DERMATONE WITH BLADE 158.00 1321020376 STRAP DOVER CATH 11.00 1321020381 DRAIN JACKSON PRATT W RESERVOI 105.00 1321020383 DRAIN JACKSON-PRATT 62.00 1321020384 DRAIN T 5 INCH ALL SIZES 28.00 1321020391 DRESSING GELFOAM SPONGE SZ LRG 90.00 1321020399 DRESSING SURGICEL 124.00 1321020404 DRILL BIT 45.00 1321020412 TUBE EAR ALL SIZES 86.00 1321020448 ENDO KITTNER 34.00 1321020450 SUTURE DEVICE ENDO 459.00 1321020451 SUTURE RELOAD ENDO 72.00 1321020452 POUCH ENDOCATCH SPECIMEN 480.00 1321020453 ELECTRODE HOOK ENDO 178.00 1321020454 IRRIGATOR STRYKER ENDO-FLO 231.00 1321020455 ENDOLOOP EACH 64.00 1321020456 ENDOPATH EZ45G 864.00 1321020457 ENDOPATH ZR45B/ZR45G (RELOAD) 350.00 1321020485 ESMARK 49.00 1321020488 LIGACLIPS ETHICON 190.00 1321020492 FIXTURES EXTERNAL 2,400.00 1321020533 STAPLER GIA 35V 833.00 1321020535 AUTOSUTURE GIA-60 RELOADER 281.00 1321020536 AUTOSUTURE GIA-60 STAPLER 448.00 1321020537 AUTOSUTURE GIA-80 RELOADER 358.00 1321020538 GIA-80 STAPLERAUTOSUTURE 594.00 1321020541 PATCH GORTEX SOFT TISSUE 1,884.00 1321020565 SUPPLIES GRAM 890.00 1321020568 CATH GROSHONG MULTI LUMEN KIT7 1,018.00 1321020577 GUIDEWIRE GLIDEWIRES 154.00 1321020581 GUIDEWIRE J&J CORDIS 503SERIES 251.00 1321020588 GUIDEWIRE URO 77.00 1321020593 HARDWARE VAR SUP 1321020625 SUPPLIES HEMI ARTHROPLASTY 743.00 1321020626 HEMICLIPS MEDIUM 90.00 1321020636 SUPPLIES HIP PINNING 445.00 1321020637 FORCEPS DISP HOT BIOPSY 124.00 1321020641 IMMOBILIZER KNEE 217.00 1321020644 IMPLANT DEVICE TVT J&J510041 2,578.00 1321020646 IMPLANTS TOE 528.00 1321020661 LENS INTRAOCCULAR 3,454.00 1321020669
Recommended publications
  • Learner Notification International Society for Heart & Lung

    Learner Notification International Society for Heart & Lung

    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
  • Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: a Pharmacokinetics, Pharmacodynamics, and Safety Study

    Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: a Pharmacokinetics, Pharmacodynamics, and Safety Study

    Adv Ther (2020) 37:3916–3928 https://doi.org/10.1007/s12325-020-01439-2 ORIGINAL RESEARCH Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study Zining Wang . Xia Zhao . Pengkang He . Shuqing Chen . Jie Jiang . Akiko Harada . Steven Brooks . Yimin Cui Received: May 25, 2020 / Published online: July 20, 2020 Ó The Author(s) 2020 ABSTRACT b.i.d., oral). After a washout period, the 12 subjects again received dabigatran etexilate Introduction: Idarucizumab is a humanized (220 mg b.i.d., oral) and idarucizumab monoclonal antibody fragment that specifically (2.5 ? 2.5 g, intravenous) 2 h after the last binds to dabigatran with high affinity and administration of dabigatran etexilate. reverses its anticoagulant effect. This study Results: The geometric mean (gMean) values of investigated the pharmacokinetics (PK) and area under the plasma concentration–time pharmacodynamics (PD) of idarucizumab in curve (AUC0–?) and maximum concentration healthy Chinese subjects at steady state of (Cmax) were 44,200 nmol h/L and 30,900 nmol/ dabigatran and explored the effect of idaru- L, respectively. An amount of 35.3 lmol of cizumab on PK and PD of dabigatran. idarucizumab, corresponding to 33.8% of the Methods: Twelve subjects received dabigatran total dose, was excreted by urine over 72 h. The etexilate treatment alone (220 mg twice daily, area under the effect (AUECabove,2–12) in the presence and absence of idarucizumab was close to zero for all coagulation parameters, diluted Zining Wang and Xia Zhao contributed equally to this work. thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time Digital Features To view digital features for this article (aPTT), and thrombin time (TT), which indi- go to https://doi.org/10.6084/m9.figshare.12613334.
  • Reversal of Oral Anticoagulation in Patients with Acute Intracerebral Hemorrhage Joji B

    Reversal of Oral Anticoagulation in Patients with Acute Intracerebral Hemorrhage Joji B

    Kuramatsu et al. Critical Care (2019) 23:206 https://doi.org/10.1186/s13054-019-2492-8 REVIEW Open Access Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage Joji B. Kuramatsu* , Jochen A. Sembill and Hagen B. Huttner Abstract In light of an aging population with increased cardiovascular comorbidity, the use of oral anticoagulation (OAC) is steadily expanding. A variety of pharmacological alternatives to vitamin K antagonists (VKA) have emerged over recent years (direct oral anticoagulants, DOAC, i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) which show a reduced risk for the occurrence of intracerebral hemorrhage (ICH). Yet, in the event of ICH under OAC (OAC-ICH), hematoma characteristics are similarly severe and clinical outcomes likewise substantially limited in both patients with VKA- and DOAC-ICH, which is why optimal acute hemostatic treatment in all OAC-ICH needs to be guaranteed. Currently, International Guidelines for the hemostatic management of patients with OAC-ICH are updated as several relevant large-sized observational studies and recent trials have established treatment approaches for both VKA- and DOAC-ICH. While the management of VKA-ICH is mainly based on the immediate reversal of elevated levels of international normalized ratio using prothrombin complex concentrates, hemostatic management of DOAC-associated ICH is challenging requiring specific antidotes, notably idarucizumab and andexanet alfa. This review will provide an overview of the latest studies and trials on hemostatic reversal agents and timing and summarizes the effects on hemorrhage progression and clinical outcomes in patients with OAC-ICH. Keywords: Intracerebral hemorrhage, Anticoagulation reversal, Tranexamic acid, Ciraparantag, Desmopressin Introduction importantly have a greater frequency of hematoma ex- Of all stroke sub-types, intracerebral hemorrhage (ICH) pansion (HE), all of which are significant outcome pre- constitutes roughly 15% and is associated with the worst dictors determining an even poorer prognosis [11–13].
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD August 2016 CONTENTS General Toxicology 6 Metals 30 Management 14 Pesticides 31 Drugs 16 Chemical Warfare 33 Chemical Incidents & 24 Plants 34 Pollution Chemicals 25 Animals 34 CURRENT AWARENESS PAPERS OF THE MONTH Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Clin Toxicol 2016; 54: 568-75. Context An increasing number of new psychoactive substances (NPS) of different chemical classes have become available through marketing and sale over the Internet. This report from the Swedish STRIDA project presents the prevalence, laboratory results, and clinical features in a series of intoxications involving the stimulant NPS -pyrrolidinovalerophenone (-PVP), a potent dopamine re-uptake inhibitor, over a 4-year period. Study design Observational case series of consecutive patients with admitted or suspected intake of NPS presenting to hospitals in Sweden from 2012 to 2015. Patients and methods In the STRIDA project, blood and urine samples are collected from intoxicated patients with admitted or suspected intake of NPS or unknown drugs presenting to hospitals over the country. Analysis of NPS is performed by mass spectrometry multicomponent methods. Clinical data are collected when caregivers consult the Swedish Poisons Information Centre Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England 2 (PIC), and retrieved from medical records.
  • 2015 Annual Report

    2015 Annual Report

    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
  • Personalized Medicine for Reconstruction of Critical-Size Bone

    Personalized Medicine for Reconstruction of Critical-Size Bone

    www.nature.com/npjregenmed ARTICLE OPEN Personalized medicine for reconstruction of critical-size bone defects – a translational approach with customizable vascularized bone tissue ✉ Annika Kengelbach-Weigand 1 , Carolina Thielen 1, Tobias Bäuerle2, Rebekka Götzl 1,5, Thomas Gerber3, Carolin Körner4, Justus P. Beier1,5, Raymund E. Horch 1 and Anja M. Boos1,5 Tissue engineering principles allow the generation of functional tissues for biomedical applications. Reconstruction of large-scale bone defects with tissue-engineered bone has still not entered the clinical routine. In the present study, a bone substitute in combination with mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC) with or without growth factors BMP-2 and VEGF-A was prevascularized by an arteriovenous (AV) loop and transplanted into a critical-size tibia defect in the sheep model. With 3D imaging and immunohistochemistry, we could show that this approach is a feasible and simple alternative to the current clinical therapeutic option. This study serves as proof of concept for using large-scale transplantable, vascularized, and customizable bone, generated in a living organism for the reconstruction of load-bearing bone defects, individually tailored to the patient’s needs. With this approach in personalized medicine for the reconstruction of critical-size bone defects, regeneration of parts of the human body will become possible in the near future. npj Regenerative Medicine (2021) 6:49 ; https://doi.org/10.1038/s41536-021-00158-8 1234567890():,; INTRODUCTION vascular networks consisting of endothelial cells can be created Therapeutic options for bone defects that cannot heal sponta- directly within tissue replacement materials7. Vascularization may neously, the so-called critical-size bone defects, are still limited be further supported by the addition of endothelial cells and and often associated with a great social burden.
  • Medications in Pregnancy & Lactation.Xlsx

    Medications in Pregnancy & Lactation.Xlsx

    Commonly Used Medications in Pregnancy and Lactation Breastfeeding Medications: Indication & Side Notes Comments Acne: Over the counter acne medications are low risk. Acne ● Benzoyl Peroxide products Acne Low risk Clindamycin topical Acne Low risk Erythromycin topical Acne Low risk *Finacea topical Acne Not recommended Proactiv Acne Low risk Salicylic Acid products Acne Low risk Allergies: Actifed (after 13 weeks) Nasal Congestion, Allergies Low risk Afrin Nasal Spray (only for 3 days) Nasal Congestion Low risk Low risk (may ↓ milk Alavert (Loratadine) Allergies supply) Low risk (may ↓ milk Benadryl (Diphenhydramine) Allergies & Nasal Congestion supply) Low risk (may ↓ milk Clarinex Allergies supply) Low risk (may ↓ milk Claritin (Loratadine) Allergies supply) Low risk (may ↓ milk Claritin D (after 13 weeks) Allergies & Nasal Congestion supply) Low risk (may ↓ milk Chlor-Trimeton Allergies supply) Flonase Rhinitis, Seasonal Allergies Low risk Phenylephrine (after 13 weeks) Nasal Congestion use caution Ocean’s Nasal Spray Allergies & Nasal Congestion Low risk Low risk (may ↓ milk Sudafed (Pseudoephedrine) (after 13 weeks) Nasal Congestion supply) Low risk (may ↓ milk Tavist (Clemastine) Allergies supply) ● Please Contact Your Pediatrician concerning use in breast feeding. * Prescription medications Low risk (may ↓ milk Zyrtec Allergies supply) Antibiotics: *Amoxicillin Infection Low risk *Ampicillin Infection Low risk *Augmentin Infection Low risk *Keflex (Cephalexin) Infection Low risk *Cefuroxime Infection Low risk *Duricef (Cefadroxil)
  • No. 33981 2 No

    No. 33981 2 No

    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
  • Mcneil Consumer : Mdl No

    Mcneil Consumer : Mdl No

    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
  • Pdfs/ Ommended That Initial Cultures Focus on Common Pathogens, Pscmanual/9Pscssicurrent.Pdf)

    Pdfs/ Ommended That Initial Cultures Focus on Common Pathogens, Pscmanual/9Pscssicurrent.Pdf)

    Clinical Infectious Diseases IDSA GUIDELINE A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya J. Michael Miller,1 Matthew J. Binnicker,2 Sheldon Campbell,3 Karen C. Carroll,4 Kimberle C. Chapin,5 Peter H. Gilligan,6 Mark D. Gonzalez,7 Robert C. Jerris,7 Sue C. Kehl,8 Robin Patel,2 Bobbi S. Pritt,2 Sandra S. Richter,9 Barbara Robinson-Dunn,10 Joseph D. Schwartzman,11 James W. Snyder,12 Sam Telford III,13 Elitza S. Theel,2 Richard B. Thomson Jr,14 Melvin P. Weinstein,15 and Joseph D. Yao2 1Microbiology Technical Services, LLC, Dunwoody, Georgia; 2Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 3Yale University School of Medicine, New Haven, Connecticut; 4Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland; 5Department of Pathology, Rhode Island Hospital, Providence; 6Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; 7Department of Pathology, Children’s Healthcare of Atlanta, Georgia; 8Medical College of Wisconsin, Milwaukee; 9Department of Laboratory Medicine, Cleveland Clinic, Ohio; 10Department of Pathology and Laboratory Medicine, Beaumont Health, Royal Oak, Michigan; 11Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire; 12Department of Pathology and Laboratory Medicine, University of Louisville, Kentucky; 13Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts; 14Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois; and 15Departments of Medicine and Pathology & Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey Contents Introduction and Executive Summary I.
  • Geisinger Lewistown Hospital Published: March 25, 2019

    Geisinger Lewistown Hospital Published: March 25, 2019

    Geisinger Lewistown Hospital Published: March 25, 2019 DESCRIPTION CHARGE Fine needle aspiration; without imaging guidance $ 607.00 Fine needle aspiration; without imaging guidance $ 286.00 Fine needle aspiration; with imaging guidance $ 2,218.00 Fine needle aspiration; with imaging guidance $ 1,691.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; first lesion $ 1,979.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; each $ 1,385.00 additional lesion (List separately in addition to code for primary procedure) Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single $ 657.00 Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or $ 986.00 multiple Incision and drainage of pilonidal cyst; simple $ 657.00 Incision and drainage of pilonidal cyst; complicated $ 3,726.00 Incision and removal of foreign body, subcutaneous tissues; simple $ 1,694.00 Incision and removal of foreign body, subcutaneous tissues; complicated $ 4,710.00 Incision and drainage of hematoma, seroma or fluid collection $ 3,470.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 1,272.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 657.00 Incision
  • SAMHSA DTAB Minutes

    SAMHSA DTAB Minutes

    Department of Health and Human Services (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board June 11-12, 2019 Minutes – Open Session SAMHSA’s CSAP Drug Testing Advisory Board (DTAB) convened on June 11-12, 2019. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 9:30 a.m. to 4:30 p.m. A final presentation/discussion on Regulatory Program Requirements was scheduled for the open session on June 12, 2019 and is included herein. Table of Contents Board Members in Attendance ................................................................................................1 Call to Order ............................................................................................................................2 Welcome and Introductory Remarks ........................................................................................ 2 Department of Transportation (DOT) Update ........................................................................... 3 Nuclear Regulatory Commission 10 CFR Part 26 Fitness for Duty Program Update, .............. 5 Department of Defense Drug Testing Update .......................................................................... 7 Program Updates by DWP (Urine, Oral Fluid, and Hair Mandatory Guidelines) ....................... 8 Update on Emerging Marijuana Legalization ........................................................................... 9 Drug Testing Index (DTI) Data: